Source: GlobalData
Three CAR-T therapies to capture over 70% of T-Cell immunotherapy market in 2025, forecasts GlobalData
Posted in Pharma
T-cell immunotherapies (TCI) are redefining cancer care, with chimeric antigen receptor T-cell (CAR-T) therapies witnessing significant momentum. In 2025, just three drugs- Carvykti by Legend Biotech, Yescarta by Gilead Sciences, and Breyanzi by Bristol-Myers Squibb (BMS)– are expected to capture over 70% of the global T-cell immunotherapy market, according to GlobalData, a leading data and analytics company.
GlobalData’s latest report “T-Cell Immunotherapy Landscape: Comprehensive Analysis of Current Drugs and Dynamics,” reveals that the TCI space is entering a new growth phase, driven by clinical success and investor confidence. Sales are forecast to double between 2024 and 2027, as CAR-T therapies continue expanding beyond blood cancers into solid tumors.
Eleni Tokali, Pharma Analyst at GlobalData, comments: “Cavykti, Yescarta, and Breyanzi are not only setting the standard for CAR-T therapies- but they are also poised to capture a massive share of the TCI market in 2025 alone, which highlights their impact and commercial momentum.”
Currently, CAR-T therapies account for 73% of all T-cell therapies in the pipeline- five times more than TCR-based therapies. Of the 16 approved TCI drugs to date, 13 are CAR-Ts, primarily targeting hematological malignancies. Despite this, TCR-based therapies and other T-cell approaches are gaining traction, and their expanded potential in solid tumors is becoming a major focus in research.
Tokali adds: “CAR-T therapies are at the forefront of T-cell immunotherapy, but the entire space, including TCR-based therapies, is advancing rapidly.”
GlobalData projects 44 new TCI drug approvals by 2029, with 18 expected in 2027 alone.
Tokali concludes: “The TCI market has seen an incredible surge in deal activity, with a 1,600% increase in deal volume from 2010 to 2024. In 2023 alone, 226 deals were recorded, with equity offerings making up 44% of all financing activity, signalling growing investor confidence in the field.”